Edition:
United Kingdom

Genmab A/S (GEN.CO)

GEN.CO on Copenhagen Stock Exchange

922.40DKK
19 Oct 2018
Change (% chg)

kr.-13.20 (-1.41%)
Prev Close
kr.935.60
Open
kr.930.40
Day's High
kr.938.80
Day's Low
kr.908.20
Volume
220,087
Avg. Vol
184,371
52-wk High
kr.1,348.00
52-wk Low
kr.823.80

Latest Key Developments (Source: Significant Developments)

Genmab Q3 Net Sales of Darzalex (Daratumumab) at $498 Mln
Tuesday, 16 Oct 2018 

Oct 16 (Reuters) - Genmab ::REG-GENMAB ANNOUNCES NET SALES OF DARZALEX® (DARATUMUMAB) FOR THIRD QUARTER OF 2018.NET SALES OF DARZALEX IN Q3 OF 2018 TOTALED USD 498 MILLION.WILL RECEIVE ROYALTIES ON WORLDWIDE NET SALES FROM JANSSEN BIOTECH, INC..GROWTH WAS PARTIALLY OFFSET BY A ONE-TIME ADJUSTMENT OUTSIDE U.S. RELATED TO ACCRUALS FOR RETROACTIVE PRICING ADJUSTMENTS.ADJUSTMENTS NEGATIVELY IMPACTED THIS WORLDWIDE OPERATIONAL GROWTH BY 16 PERCENTAGE POINTS..2018 Q3 NET SALES WERE USD 318 MILLION IN U.S. AND USD 180 MILLION IN REST OF WORLD..  Full Article

Genmab: European Marketing Authorization For Darzalex (Daratumumab) For Front Line Multiple Myeloma
Friday, 31 Aug 2018 

Aug 31 (Reuters) - Genmab A/S ::REG-GENMAB ANNOUNCES EUROPEAN MARKETING AUTHORIZATION FOR DARZALEX® (DARATUMUMAB) FOR FRONT LINE MULTIPLE MYELOMA.DARZALEX APPROVED IN EUROPE IN COMBINATION WITH BORTEZOMIB, MELPHALAN AND PREDNISONE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA.APPROVAL FOLLOWS POSITIVE OPINION BY EUROPEAN COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE.WILL RECEIVE A MILESTONE PAYMENT OF USD 13 MILLION FROM JANSSEN IN CONNECTION WITH FIRST COMMERCIAL SALES OF DARZALEX UNDER EXPANDED LABEL.SALES ARE EXPECTED TO OCCUR QUICKLY AFTER APPROVAL.  Full Article

Genmab Q2 Operating Result at DKK 135 mln
Wednesday, 8 Aug 2018 

Aug 8 (Reuters) - Genmab A/S ::REG-GENMAB ANNOUNCES FINANCIAL RESULTS FOR THE FIRST HALF OF 2018.IS MAINTAINING ITS 2018 FINANCIAL GUIDANCE PUBLISHED ON FEBRUARY 21, 2018.REVENUE WAS DKK 1,191 MILLION IN FIRST HALF OF 2018 COMPARED TO DKK 1,024 MILLION IN FIRST HALF OF 2017.OPERATING INCOME WAS DKK 459 MILLION IN FIRST HALF OF 2018 COMPARED TO DKK 582 MILLION IN FIRST HALF OF 2017.Q2 REVENUE DKK 509.7 MILLION (REUTERS POLL DKK 460 MILLION).Q2 OPERATING RESULT DKK 135.0 MILLION (REUTERS POLL DKK 79.1 MILLION).ROYALTY INCOME AMOUNTED TO DKK 709 MILLION IN THE FIRST HALF OF 2018 COMPARED TO DKK 479 MILLION IN THE FIRST HALF OF 2017.MILESTONE INCOME WAS DKK 40 MILLION IN THE FIRST HALF OF 2018 WHICH WAS DRIVEN BY THE JANSSEN AND NOVO NORDISK DUOBODY COLLABORATIONS.  Full Article

Genmab Q2 DARZALEX Net Sales At USD 511 Million
Tuesday, 17 Jul 2018 

July 17 (Reuters) - GENMAB A/S ::REG-GENMAB ANNOUNCES NET SALES OF DARZALEX® (DARATUMUMAB) FOR SECOND QUARTER OF 2018.NET SALES OF DARZALEX IN Q2 OF 2018 TOTALED USD 511 MILLION.WILL RECEIVE ROYALTIES ON WORLDWIDE NET SALES FROM JANSSEN BIOTECH, INC..NET SALES WERE USD 298 MILLION IN U.S. AND USD 213 MILLION IN REST OF WORLD..  Full Article

Genmab Enters Strategic Partnership With Immatics
Thursday, 12 Jul 2018 

July 12 (Reuters) - Genmab A/S ::REG-GENMAB ENTERS STRATEGIC PARTNERSHIP WITH IMMATICS TO DISCOVER AND DEVELOP NEXT GENERATION BISPECIFIC CANCER IMMUNOTHERAPIES.ENTERED INTO A RESEARCH COLLABORATION AND EXCLUSIVE LICENSE AGREEMENT WITH PRIVATELY OWNED IMMATICS BIOTECHNOLOGIES GMBH.IMMATICS TO RECEIVE UPFRONT PAYMENT OF USD 54 MILLION FROM GENMAB.WILL RECEIVE AN EXCLUSIVE LICENSE TO THREE PROPRIETARY TARGETS FROM IMMATICS.NEWS DOES NOT IMPACT GENMAB'S 2018 FINANCIAL GUIDANCE.  Full Article

Genmab Says Will Increase Share Capital By 155,576 Shares
Tuesday, 15 May 2018 

May 15 (Reuters) - Genmab A/S ::CAPITAL INCREASE IN GENMAB AS A RESULT OF EMPLOYEE WARRANT EXERCISE.WILL INCREASE ITS SHARE CAPITAL BY 155,576 SHARES AS A CONSEQUENCE OF THE EXERCISE OF EMPLOYEE WARRANTS.INCREASE CORRESPONDS TO APPROX. 0.25 % OF THE COMPANY'S SHARE CAPITAL.TOTAL NOMINAL VALUE OF SHARE CAPITAL AFTER INCREASE IS DKK 61,436,818 CORRESPONDING TO 61,436,818 VOTES.  Full Article

Genmab Q1 Operating Result DKK 324 Million, Below Expectations
Tuesday, 8 May 2018 

May 8 (Reuters) - Genmab A/S ::REG-INTERIM REPORT FIRST QUARTER 2018.REVENUE WAS DKK 681 MILLION IN Q1 OF 2018 COMPARED TO DKK 251 MILLION IN Q1 OF 2017.OPERATING INCOME WAS DKK 324 MILLION IN Q1 OF 2018 COMPARED TO DKK 46 MILLION IN Q1 OF 2017.IS MAINTAINING ITS 2018 FINANCIAL GUIDANCE PUBLISHED ON FEBRUARY 21, 2018..Q1 REVENUE DKK 681 MILLION (REUTERS POLL DKK 684 MILLION).Q1 OPERATING RESULT DKK 324 MILLION (REUTERS POLL DKK 358 MILLION).OPERATING EXPENSES WERE DKK 357 MILLION IN Q1 OF 2018 COMPARED TO DKK 205 MILLION IN Q1 OF 2017.Q1 NET PROFIT DKK 198.6 MILLION (REUTERS POLL DKK 282 MILLION).  Full Article

Genmab gets U.S. FDA approval of Darzalex in newly diagnosed multiple Myeloma
Monday, 7 May 2018 

May 7 (Reuters) - Genmab A/S ::REG-GENMAB ANNOUNCES U.S. FDA APPROVAL OF DARZALEX (DARATUMUMAB) IN NEWLY DIAGNOSED MULTIPLE MYELOMA.GENMAB - FDA SUBSEQUENTLY GRANTED PRIORITY REVIEW TO SUPPLEMENTAL BIOLOGICS LICENSE APPLICATION, WITH PRESCRIPTION DRUG USER FEE ACT TARGET DATE OF MAY 21.  Full Article

Genmab: Q1 Net Sales Of Darzalex At $432 Mln
Tuesday, 17 Apr 2018 

April 17 (Reuters) - Genmab A/S ::REG-GENMAB ANNOUNCES NET SALES OF DARZALEX® (DARATUMUMAB) FOR FIRST QUARTER OF 2018.REG-GENMAB ANNOUNCES NET SALES OF DARZALEX® (DARATUMUMAB) FOR FIRST QUARTER OF 2018.NET SALES OF DARZALEX IN Q1 OF 2018 TOTALED USD 432 MILLION.WILL RECEIVE ROYALTIES ON WORLDWIDE SALES FROM JANSSEN BIOTECH, INC.  Full Article

Genmab 2017 Net Sales Of DARZALEX At $1.24 Billion
Tuesday, 23 Jan 2018 

Jan 23 (Reuters) - GENMAB ::ANNOUNCES 2017 NET SALES FIGURES FOR DARZALEX® (DARATUMUMAB).‍WORLDWIDE NET SALES OF DARZALEX (DARATUMUMAB) AS REPORTED BY JOHNSON & JOHNSON WERE USD 1,242 MILLION IN 2017​.‍NET SALES WERE USD 884 MILLION IN U.S. AND NET SALES IN REST OF WORLD WERE USD 358 MILLION​.  Full Article

Pfizer bets on biotech flu vaccine in $425 mln BioNTech alliance

FRANKFURT, Aug 16 Pfizer has agreed to pay German biotech firm BioNTech up to $425 million in an alliance to develop more effective influenza jabs, the latest among several major pharma companies to bank on a promising new genetic approach.